The prognostic value of the Tau protein serum level in metastatic breast cancer patients and its correlation with brain metastases.

ABSTRACT:

Background

Metastatic breast cancer (MBC) prognosis is variable, depending on several clinical and biological factors. A better prediction of a patient's outcome could allow for a more accurate choice of treatments. The role of serum biomarkers in predicting outcome remains unclear in this setting. Tau, a microtubule-associated protein, is a neuronal marker that is also expressed in normal breast epithelial cells and cancer cells. Its tissue expression is associated with prognosis in MBC. However, the prognostic value of Tau serum levels in these patients is unknown. We aimed at evaluating the prognostic value of Tau (and other classical biomarkers) in MBC patients, and to assess its association with the presence of brain metastases (BM).

Methods

244 MBC patients treated at

SUBMITTER: Darlix A 

PROVIDER: S-EPMC6354387 | biostudies-literature | 2019 Jan

REPOSITORIES: biostudies-literature